The Peptide Proven to Reduce Visceral Fat (In Randomized Controlled Trials)

Tesamorelin can selectively reduce visceral fat, as demonstrated in RCTs. But the real story is what it reveals about metabolism, peptides, and the future of self-driven health experimentation...

If there’s one type of fat I fear, it’s visceral fat.

Not the jiggly stuff under your skin—which I know our egos and vanity love to hate—but the fat you can’t see.

The kind that wraps itself around your internal organs and quietly secretes inflammatory molecules that chip away at your metabolic health and drive cardiometabolic disease.

In short: if there’s one type of fat you don’t want, it’s visceral fat.

Which makes this question incredibly interesting…

What if we could selectively target and reduce visceral fat?

Because even in people who look lean on the outside, reducing visceral fat could meaningfully improve metabolic health.

Now, I know what you’re thinking. Spot reduction?

That sounds like fitness industry mythology.

But in this case—it’s not.

It’s actually backed by multiple double-blinded human randomized controlled trials using a peptide called: tesamorelin.

Now, before I lose you, let me hook you with this graph: In a double-blind, placebo-controlled 26-week study, patients given tesamorelin saw about a 15% reduction in visceral fat, while the placebo group actually trended upward (A).

The dot plot on the right (B) simply shows that people who has more visceral fat to lose, lost more visceral fat on tesamorelin. Makes sense.

*In a 26-week randomized controlled trial, tesamorelin caused 15% visceral fat loss as compared to modest visceral fat gain in the placebo group. Larger visceral fat reductions were seen in those with higher baseline visceral fat levels.

Even more interesting?

This reduction was specific to visceral fat, not subcutaneous fat.

Yeah… that should make you pause.

• So, what’s going on here?

• What’s the mechanism?

• And is there a way to use this safely and effectively?

Let’s rewinds and introduce the background biology. Then we will return to the clinical trials and practical protocols.

What Is Tesamorelin?

Tesamorelin is an analog of growth hormone–releasing hormone (GHRH).

It’s not growth hormone itself, but something that stimulates your body to produce growth hormone naturally from the pituitary gland, which sits just beneath your brain.

Under normal physiology, GHRH from the hypothalamus signals the anterior pituitary to release growth hormone in pulses, especially during sleep.

That detail matters.

Because when you inject growth hormone directly, you override that natural rhythm. You get a more sustained, non-physiologic elevation. And that’s where side effects start to creep in: joint pain, fluid retention, insulin resistance, even increased cancer risk in certain contexts. In extreme cases, you can develop acromegaloid features, with excess growth of bones and soft tissues

Tesamorelin, on the other hand, works upstream.

Tesamorelin stimulates your pituitary to release growth hormone in a more physiologic, pulsatile pattern, preserving the natural dynamics of the system.

Structurally, it’s essentially a modified version of GHRH with a small molecular addition that increases its stability, allowing it to be used therapeutically.

Now here’s the key point:

• Growth hormone is strongly lipolytic, i.e. it promotes fat breakdown.

• And importantly, visceral fat is more responsive to growth hormone than subcutaneous fat.

So, the logic is fairly straightforward: If you can safely enhance natural growth hormone signaling with tesamorelin, you might be able to selectively reduce visceral fat and improve cardiometabolic health.

*The GHRH-GH-IGF-1 Axis: The brain’s hypothalamus signals via growth hormone releasing hormone (GHRH) to the pituitary under the brain to release growth hormone (GH), which has direct effects on muscle, bone, and fat, and stimulates the release of insulin-like growth factor-1 (IGF-1). Tesamorelin is an analog of GHRH.

That’s the idea at least.

Now, before we get into the studies, there’s one important piece of context.

The FDA-Approved Indication

Most of the clinical trials on tesamorelin were conducted in HIV patients. In fact, the FDA-approved indication is to reduce visceral abdominal fat in HIV-associated lipodystrophy.

And this isn’t because HIV itself causes visceral fat gain.

It’s largely due to the treatments (antiretroviral therapies), which can lead to a preferential accumulation of visceral fat through a mix of mechanisms, including causing mitochondrial dysfunction and insulin resistance.

So, historically, patients with HIV treated with antiretroviral therapies have been the vulnerable group in which tesamorelin has been studied and approved.

Although that doesn’t mean the results to generalize to patients without HIV or who aren’t on antiretroviral therapies. It’s just a commentary on the available data.

Now, let’s get it.

The Randomized Controlled Trials

Let’s rewind to 2007. A paper was published in the most impactful medical journal in the world, The New England Journal of Medicine, where 412 patients with HIV were randomized to receive either 2 mg of tesamorelin or placebo for 26 weeks.

The primary endpoint? Change in visceral adipose tissue, measured by CT scan.

And the results were impressive.

Visceral fat decreased by 15.2% in the tesamorelin group, while but increasing by about 5% in the placebo group.

That’s the graph I showed you earlier.

*As above.

Alongside this, there were corresponding improvements in metabolic health markers like triglycerides and HDL cholesterol.

Notably, the effect was specific to visceral fat, that inflammatory fat that wraps around your internal organs. Subcutaneous fat did not change to any clinically meaningful extent.

So, we are indeed seeing a selective effect on visceral fat.

And from a safety standpoint, there was no statistically significant difference in adverse events between the tesamorelin and placebo groups.

Quoting from the paper:

“In summary, treatment with tesamorelin during a 6-month period resulted in a highly significant and selective reduction in visceral fat.”

And, importantly, this wasn’t a one-off finding.

These results have been replicated multiple times.

For example, in 2014, a double-blind, randomized placebo-controlled trial published in JAMA followed a similar design, with patients randomized to tesamorelin (2 mg) or a placebo for six months.

Once again, tesamorelin delivered.

Visceral fat decreased by about 34 cm² in the treatment group, while it increased by roughly 8 cm² in the placebo group. There were also modest but consistent reductions in liver fat. And again, the effect was highly selective, with minimal change in subcutaneous fat.

*In this randomized placebo-controlled trial, tesamorelin caused a 34 cm² decrease in visceral fat. Subcutaneous fat did not decrease, and lean mass trending upwards as compared to placebo.

And what about lean mass?

Well, there was no loss of lean mass and, if anything, lean mass trended upward from about 60.7 to 61.5 kg, which makes complete sense given that tesamorelin acts as a growth hormone secretagogue.

And, again, the adverse events rates were similar between the tesamorelin and placebo groups. To be clear, this doesn’t rule out the possibility of any adverse effects caused by the peptide; however, it’s at least moderately reassuring.

*Adverse even rate was similar between the tesamorelin and placebo groups. More below.

TL;DR (Summary)

• ~15% reduction in visceral fat

• Minimal change in subcutaneous fat

• No major safety signal in randomized controlled trials

This is one of the few interventions shown to selectively reduce visceral fat in humans.

Now here’s where things get interesting.

Because the dosing protocol used in clinical trials… may not actually be the most biologically optimal approach.

In the rest of this letter for StayCurious Metabolism Premium members, we will dive into:

• How people are using tesamorelin in the real world (biohackers, Silicon Valley, etc.)

• Dosing and protocols, including frequency, cycling, timing, and what to track to optimize benefits while minimizing risk.

• Peptide and supplement stacks: What’s being combined, and why, for (i) muscle gain, (ii) fat loss, and (iii) insulin sensitivity.

To be clear, none of this is medical advice or recommendations. But in a world where these compounds are increasingly accessible, it’s not enough to ignore conversations or moralize them. Much like sex ed, the more responsible approach is education—not information abstinence. Let’s practice safe peptides…